American Society of Hematology

SHERPA: Blue

People

  1. Zelenetz
    Zelenetz
  2. O'Reilly
    O'Reilly
  3. Van Den Brink
    Van Den Brink
  4. Levine
    Levine
  5. Kernan
    Kernan
  6. Tallman
    Tallman
  7. Moore
    Moore
  8. Giralt
    Giralt
  9. Horwitz
    Horwitz
  10. Young
    Young

Groups

  1. Hematologic Oncology, Division of (1312)
  2. Leukemia Disease Management Team (1074)
  3. Sloan Kettering Institute Faculty (735)
  4. Leukemia Service (501)
  5. Lymphoma Disease Management Team (485)
  6. Adult Bone Marrow Transplant (BMT) Service (446)
  7. Myeloma Disease Management Team (434)
  8. Hematologic Oncology Disease Management Team (404)
  9. Lymphoma Service (398)
  10. Pediatrics, Department of (378)
Search Within
Refine Results
Formats
  1. Meeting Abstract (1641)
  2. Journal Article (633)
Groups
  1. Hematologic Oncology, Division of (1312)
  2. Leukemia Disease Management Team (1074)
  3. Sloan Kettering Institute Faculty (735)
  4. Leukemia Service (501)
  5. Lymphoma Disease Management Team (485)
  6. Adult Bone Marrow Transplant (BMT) Service (446)

More Groups

People
  1. Andrew Zelenetz (181)
  2. Richard O'Reilly (172)
  3. Stephen Nimer (151)
  4. Marcel Van Den Brink (141)
  5. Ross Levine (137)
  6. Nancy Kernan (133)

More People

Years
  1. 2018 (18)
  2. 2017 (65)
  3. 2016 (31)
  4. 2015 (228)
  5. 2014 (230)
  6. 2013 (163)

More Years

Publications
  1. Blood (2233)
  2. Hematology-American Society of Hematology Education Program (24)
  3. Blood Advances (17)

Results (2274)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: Phase 1 results and long-term follow-up
    Journal Article

    Kreitman, R. J.; Tallman, M. S.; Robak, T.; Coutre, S.; Wilson, W. H.; Stetler-Stevenson, M.; FitzGerald, D. J.; Santiago, L.; Gao, G.; Lanasa, M. C.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
    Journal Article

    Stein, E. M.; Garcia-Manero, G.; Rizzieri, D. A.; Tibes, R.; Berdeja, J. G.; Savona, M. R.; Jongen-Lavrenic, M.; Altman, J. K.; Thomson, B.; Blakemore, S. J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
    Journal Article

    Fanale, M. A.; Horwitz, S. M.; Forero-Torres, A.; Bartlett, N. L.; Advani, R. H.; Pro, B.; Chen, R. W.; Davies, A.; Illidge, T.; Uttarwar, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Posttransplant chimeric antigen receptor therapy
    Journal Article

    Smith, M.; Zakrzewski, J.; James, S.; Sadelain, M.
    Blood (2018)

    Fulltext@MSK | Save
  • Transplant strategies in relapsed/refractory Hodgkin lymphoma
    Journal Article

    Shah, G. L.; Moskowitz, C. H.
    Blood (2018)

    Fulltext@MSK | Save
  • Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: A CIBMTR analysis
    Journal Article

    Shah, N. N.; Ahn, K. W.; Litovich, C.; Fenske, T. S.; Ahmed, S.; Battiwalla, M.; Bejanyan, N.; Dahi, P. B.; Bolaños-Meade, J.; Chen, A. I.; more...
    Blood Advances (2018)

    Fulltext@MSK | Save
  • Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma
    Journal Article

    Kumar, A.; Vardhana, S.; Moskowitz, A. J.; Porcu, P.; Dogan, A.; Dubovsky, J. A.; Matasar, M. J.; Zhang, Z.; Younes, A.; Horwitz, S. M.
    Blood Advances (2018)

    Fulltext@MSK | Save
  • Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily
    Journal Article

    Moskowitz, C. H.
    Blood Advances (2018)

    Fulltext@MSK | Save
  • Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
    Journal Article

    Herrera, A. F.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; LaCasce, A. S.; Ansell, S. M.; Moskowitz, C. H.; Fenton, K.; more...
    Blood (2018)

    Fulltext@MSK | Save